Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Apr;23(2):89-91.
doi: 10.1093/pch/pxx172. Epub 2017 Nov 28.

Autonomic instability in a dehydrated child on guanfacine: Case report and literature review

Affiliations
Case Reports

Autonomic instability in a dehydrated child on guanfacine: Case report and literature review

Elizabeth Roach-Fox et al. Paediatr Child Health. 2018 Apr.

Abstract

An 8-year-old girl on guanfacine extended-release (GXR) for attention-deficit/hyperactivity disorder presented with somnolence, bradycardia and hypotension during a heat wave. No overdose was suspected. She was admitted to the intensive care unit for monitoring and ongoing fluid resuscitation for hypotension. Electrocardiogram showed intermittent atrioventricular dissociation. Upon restarting the drug post-discharge, blood pressures were normal, and follow-up electrocardiograms documented asymptomatic bradycardia but no dissociation. GXR is used as monotherapy or adjunct therapy in the treatment of inattention and hyperactivity in children. No published paediatric or adult study has documented atrioventricular dissociation, bradycardia or hypotension significant enough to warrant hospital admission. This case suggests that GXR can pose a hemodynamic risk to children in the context of elevated environmental temperatures and dehydration. Clinicians should be aware of this potential complication and should counsel patients about signs and symptoms of hypotension, bradycardia, bradypnea and somnolence.

Keywords: Attention-deficit/hyperactivity disorder; Drug side effects; Guanfacine; Intensive care.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Standard 12-lead ECG performed during sleep on the night of admission. Paper speed 25 mm/s. Note the atrioventricular dissociation displayed most clearly in limb lead II.

Similar articles

Cited by

References

    1. Shire Pharma Canada. Intuniv XR® Product Monograph. 2013:1–38. http://www.shirecanada.com/-/media/shire/shireglobal/shirecanada/pdffile...).
    1. Hassani SA, Oemisch M, Balcarras M et al. . A computational psychiatry approach identifies how alpha-2A noradrenergic agonist guanfacine affects feature-based reinforcement learning in the macaque. Sci Rep 2017;7:40606. - PMC - PubMed
    1. Shojaei AH, Chang R-K, Pennick M. Guanfacine extended release tablets as treatment for attention-deficit/hyperactivity disorder: Formulation characteristics. Poster presented at the US Psychiatric & Mental Health Congress; New Orleans, Louisiana, November 16–19, 2006.
    1. Canadian ADHD Resource Alliance (CADDRA) Guidelines. Chapter 7: Pharmacological Treatment of ADHD 2014. https://caddra.ca/pdfs/caddraGuidelines2011Chapter07.pdf (accessed July 19, 2017).
    1. van Zwieten PA, Chalmers JP. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc Drugs Ther 1994;8:787–99. - PubMed

Publication types

LinkOut - more resources